VAXXINITY INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
VAXXINITY INC. - More news...
VAXXINITY INC. - More news...
- Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia
- Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
- Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
- Vaxxinity to Present at Upcoming Investor Conferences in September
- Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
- Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
- Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)
- Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
- Vaxxinity to Participate at the Jefferies Healthcare Conference
- Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
- Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference
- Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
- Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
- CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
- Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster
- Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates
- Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
- Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
- Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
- Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Support UB-312 Vaccine Study
- Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors
- Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
